|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5000 CAD | -3.85% |
|
-1.96% | +9.89% |
| 06-03 | PharmaCorp Rx Initiated at Outperform, $0.70 Price Target at Raymond James | MT |
| 06-01 | Earnings Flash (PCRX.V) PharmaCorp Reports Q1 Revenue $7.2M, Up 79.4% YoY | MT |
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
Profitability | |||||
Return on Assets | - | -18.85 | -14.29 | -5.29 | -1.54 |
Return on Total Capital | - | -19.07 | -14.47 | -5.88 | -1.75 |
Return On Equity % | - | -28.02 | -18.85 | -6.4 | -3.43 |
Return on Common Equity | - | -28.02 | -18.85 | -6.21 | -3.6 |
Margin Analysis | |||||
Gross Profit Margin % | - | - | - | 37.69 | 39.72 |
SG&A Margin | - | - | - | 55.22 | 39.2 |
EBITDA Margin % | - | - | - | -23.23 | -1.98 |
EBITA Margin % | - | - | - | -24.44 | -2.78 |
EBIT Margin % | - | - | - | -27.41 | -5.92 |
Income From Continuing Operations Margin % | - | - | - | -18.14 | -6.81 |
Net Income Margin % | - | - | - | -17.48 | -7.09 |
Net Avail. For Common Margin % | - | - | - | -17.48 | -7.09 |
Normalized Net Income Margin | - | - | - | -11.83 | -2.78 |
Levered Free Cash Flow Margin | - | - | - | -9.39 | 8.86 |
Unlevered Free Cash Flow Margin | - | - | - | -9.23 | 9.03 |
Asset Turnover | |||||
Asset Turnover | - | - | - | 0.31 | 0.41 |
Fixed Assets Turnover | - | - | - | - | 4.4 |
Receivables Turnover (Average Receivables) | - | - | - | - | 27.05 |
Inventory Turnover (Average Inventory) | - | - | - | - | 6.27 |
Short Term Liquidity | |||||
Current Ratio | 37.98 | 166.01 | 50.24 | 8.59 | 5.14 |
Quick Ratio | 37.2 | 166.01 | 48.54 | 7.79 | 4.67 |
Operating Cash Flow to Current Liabilities | 0.06 | -7.3 | -11.25 | 0.07 | 0.35 |
Days Sales Outstanding (Average Receivables) | - | - | - | - | 13.49 |
Days Outstanding Inventory (Average Inventory) | - | - | - | - | 58.22 |
Average Days Payable Outstanding | - | - | - | - | 87.92 |
Cash Conversion Cycle (Average Days) | - | - | - | - | -16.21 |
Long Term Solvency | |||||
Total Debt/Equity | - | - | - | 3.12 | 8.7 |
Total Debt / Total Capital | - | - | - | 3.02 | 8 |
LT Debt/Equity | - | - | - | 2.63 | 7.65 |
Long-Term Debt / Total Capital | - | - | - | 2.55 | 7.04 |
Total Liabilities / Total Assets | 2.63 | 0.6 | 1.99 | 13.19 | 20.28 |
EBIT / Interest Expense | - | - | - | -111.38 | -21.77 |
EBITDA / Interest Expense | - | - | - | -91.06 | -5.23 |
(EBITDA - Capex) / Interest Expense | - | - | - | -91.54 | -6.77 |
Total Debt / EBITDA | - | - | - | -0.73 | -15.28 |
Net Debt / EBITDA | - | - | - | 9.19 | 71.73 |
Total Debt / (EBITDA - Capex) | - | - | - | -0.73 | -11.8 |
Net Debt / (EBITDA - Capex) | - | - | - | 9.14 | 55.41 |
Growth Over Prior Year | |||||
Total Revenues, 1 Yr. Growth % | - | - | - | - | 260.57 |
Gross Profit, 1 Yr. Growth % | - | - | - | - | 279.89 |
EBITDA, 1 Yr. Growth % | - | - | - | - | -69.19 |
EBITA, 1 Yr. Growth % | - | 607.52 | 2.62 | 145.02 | -59 |
EBIT, 1 Yr. Growth % | - | 607.52 | 2.62 | 174.82 | -22.08 |
Earnings From Cont. Operations, 1 Yr. Growth % | - | 567.6 | -9.02 | 123.4 | 35.31 |
Net Income, 1 Yr. Growth % | - | 567.6 | -9.02 | 115.3 | 46.26 |
Normalized Net Income, 1 Yr. Growth % | - | 567.6 | -9.02 | 133.07 | -15.12 |
Diluted EPS Before Extra, 1 Yr. Growth % | - | - | -10.27 | -46.58 | -4.49 |
Accounts Receivable, 1 Yr. Growth % | - | - | - | - | 272.71 |
Inventory, 1 Yr. Growth % | - | - | - | - | 106.02 |
Net Property, Plant and Equip., 1 Yr. Growth % | - | - | - | - | 36.19 |
Total Assets, 1 Yr. Growth % | - | 173.19 | -15.1 | 1.42K | 86.23 |
Tangible Book Value, 1 Yr. Growth % | - | 178.89 | -16.29 | 503.86 | 58.16 |
Common Equity, 1 Yr. Growth % | - | 178.89 | -16.29 | 1.23K | 71.11 |
Cash From Operations, 1 Yr. Growth % | - | -7.73K | 332.22 | -124.06 | 1.51K |
Capital Expenditures, 1 Yr. Growth % | - | - | - | - | 1.17K |
Levered Free Cash Flow, 1 Yr. Growth % | - | - | -1.01K | 32.59 | -440.37 |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | - | -1.01K | 30.42 | -452.68 |
Compound Annual Growth Rate Over Two Years | |||||
EBITA, 2 Yr. CAGR % | - | - | 169.46 | 58.57 | 0.23 |
EBIT, 2 Yr. CAGR % | - | - | 169.46 | 67.94 | 46.34 |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | - | 146.45 | 42.56 | 73.86 |
Net Income, 2 Yr. CAGR % | - | - | 146.45 | 39.95 | 77.45 |
Normalized Net Income, 2 Yr. CAGR % | - | - | 146.45 | 45.61 | 40.65 |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | - | -30.77 | -28.57 |
Total Assets, 2 Yr. CAGR % | - | - | 52.29 | 258.9 | 431.57 |
Tangible Book Value, 2 Yr. CAGR % | - | - | 52.79 | 124.83 | 209.05 |
Common Equity, 2 Yr. CAGR % | - | - | 52.79 | 234.19 | 377.8 |
Cash From Operations, 2 Yr. CAGR % | - | - | 1.72K | 1.97 | 96.53 |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 248.01 | 112.44 |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 245.15 | 114.47 |
Compound Annual Growth Rate Over Three Years | |||||
EBITA, 3 Yr. CAGR % | - | - | - | 161.05 | 1.02 |
EBIT, 3 Yr. CAGR % | - | - | - | 171.23 | 30.01 |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | - | 138.51 | 40.1 |
Net Income, 3 Yr. CAGR % | - | - | - | 135.59 | 42.03 |
Normalized Net Income, 3 Yr. CAGR % | - | - | - | 141.9 | 21.64 |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | - | -22.93 |
Total Assets, 3 Yr. CAGR % | - | - | - | 227.7 | 188.4 |
Tangible Book Value, 3 Yr. CAGR % | - | - | - | 141.57 | 99.96 |
Common Equity, 3 Yr. CAGR % | - | - | - | 214.64 | 167.36 |
Cash From Operations, 3 Yr. CAGR % | - | - | - | 329.71 | 155.58 |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | 245.44 |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | 247.64 |
- Stock Market
- Stocks
- PCRX Stock
- Financials PharmaCorp Rx Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















